KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
0.1855
-0.0053 (-2.78%)
At close: Oct 22, 2026, 4:00 PM EDT
0.1900
+0.0045 (2.43%)
Pre-market: Oct 23, 2026, 4:41 AM EDT
KALA BIO Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
3.59M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.89M | -7.35M | -65.37% |
| Dec 31, 2021 | 11.24M | 4.88M | 76.67% |
| Dec 31, 2020 | 6.36M | 288.00K | 4.74% |
| Dec 31, 2019 | 6.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 45.00K | -410.00K | -90.11% |
| Dec 31, 2014 | 455.00K | 405.00K | 810.00% |
| Dec 31, 2013 | 50.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
KALA News
- 23 days ago - KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception - Newsfile Corp
- 4 weeks ago - KALA BIO Proxy statement: Proxy filing - Filings
- 4 weeks ago - Kala Bio, Virotek sign letter of intent with U.S. DNA testing platform - TheFly
- 4 weeks ago - Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products - GlobeNewsWire
- 5 weeks ago - KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team - GlobeNewsWire
- 5 weeks ago - KALA BIO Proxy statement: Proxy filing - Filings
- 7 weeks ago - Kala Bio, Virotek announce exclusive distribution and reseller agreement - TheFly
- 7 weeks ago - Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program - GlobeNewsWire